Vaccines for lyssaviruses other than rabies

Expert Review of Vaccines

Volumn 4, Issue 4, 2005, Pages 533-540

  Nel, Louis H ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Crossprotection; Lyssaviruses; Rabies; Rabies related; Vaccines

Indexed keywords

IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; RABIES VACCINE;

GENOTYPE; HUMAN; MONONEGAVIRALES; NONHUMAN; PATHOGENICITY; PHYLOGENY; PRIORITY JOURNAL; PROPHYLAXIS; RABIES; REVIEW; RHABDOVIRUS; VACCINATION; VACCINE PRODUCTION; VESICULAR STOMATITIS VIRUS; VIRUS GENOME; VIRUS INFECTION; VIRUS STRAIN; VIRUS VIRULENCE;

ANIMALS; HUMANS; LYSSAVIRUS; RABIES; RHABDOVIRIDAE INFECTIONS; VIRAL VACCINES;

EID: 24744444546     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.4.4.533     Document Type: Review

References (71)

1. Tordo N, Poch O. Structure of rabies virus. In: Rabies. Campbell JB, Charlton KM (Eds). Kluwer Academic Publishers, MA, USA (1988).
2. Gaudin Y, Ruigrok RWH, Tuffereau C, Knossow M, Flamand A. Rabies virus glycoprotein is a trimer. Virology 187, 627-632 (1992).
3. Dietzschold B, Wunner WH, Wiktor TJ et al. Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. Proc. Natl Acad. Sci. USA 80, 70-74 (1983).
4. Prehaud C, Coulon P, Lafay F, Thiers C, Flamand A. Antigenicity site II of the rabies virus glycoprotein: structure and role in viral virulence. J. Virol. 62, 1-7 (1988).
5. Thoulouze MI, Lafage M, Schachner M, Hartmann U, Cremer H, Lafon M. The neural cell adhesion molecule is a receptor for rabies virus. J. Virol. 72, 7181-7190 (1998)
6. Perrin P, Thibodeau L, Sureau P. Rabies immunosomes (subunit vaccine) structure and immunogenicity. Pre and post exposure protection studies. Vaccine 3, 325 (1985).
7. Dietzschold B, Gore M, Marchandier D et al. Structural and immunological characterization of a linear virus neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine. J. Virol. 64, 3804-3809 (1990).
8. Coulon P, Lafay F, Flamand A. Rabies virus antigenicity: an overview. Onderstepoort J. Vet. Res. 60, 271-275 (1993).
9. Coll JM. The glycoprotein G of rhabdoviruses. Arch. Virol. 140, 827-851 (1995).
10. Mebatsion T, Weiland F, Conzelmann KK. Matrix protein of rabies virus is responsible for the assembly and budding of bullet-shaped particles and interacts with the transmembrane spike glycoprotein G. J. Virol. 73, 242-250 (1999).
11. Hooper DC, Pierard I, Modelska A et al. Rabies ribonucleocapsid as an oral immunogen and immunological enhancer. Proc. Natl Acad. Sci. USA 91, 10908-10912 (1994).
12. Dietzschold B, Wang H, Rupprecht C et al. Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein. Proc. Natl Acad. Sci. USA 84, 9165-9169 (1987).
13. Dietzshold B, Lafon M, Wang H et al. Analysis of protective immune mechanisms induced by rabies nucleoprotein. In: Genetics and Pathogenicity of Negative Strand Viruses. Kolakofsky D, Mahy BWJ (Eds). Elsevier Science Publishers BV, Amsterdam, The Netherlands 295-305 (1989).
14. Fu ZF, Dietzschold B, Schumacher CL, Wunner WH, Ertl HCJ, Koprowski H. Rabies virus nucleoprotein expressed in and purified from insect cells is efficacious as a vaccine. Proc. Natl Acad. Sci. USA 88, 2001-2005 (1991).
15. Fujii H, Takita-Sonoda Y, Mifune K, Kirai K, Nishizono A, Mannen K. Protective efficacy in mice of post-exposure vaccination with vaccinia virus recombinant expressing either rabies virus glycoprotein or nucleoprotein. J. Gen. Virol. 75, 1339-1344 (1994).
16. Drings A, Jallet C, Chambert B, Tordo N, Perrin P. Is there an advantage to including the nucleoprotein in a rabies glycoprotein subunit vaccine? Vaccine 17, 1549-1557 (1999).
17. Nel LH, Niezgoda M, Hanlon CA, Morril PA, Yager PA, Rupprecht CE. A comparison of DNA vaccines for the rabies-related virus, Mokola. Vaccine 21 (19-20), 2598-2606 (2003). Compares different DNA vaccines for Mokola virus, examining the utility of both the glyco- and nucleoprotein genes and describing prime-boost experiments with a commercial rabies recombinant vaccinia vaccine and a Mokola virus DNA vaccine.
18. Bourhy H, Kissi B, Tordo N. Molecular diversity of the Lyssavirus genus. Virology 194, 70-81 (1993).
19. Gould AR, Hyatt AD, Lunt R et al. Characterisation of a novel lyssavirus isolated from Pteropid bats in Australia. Virus Res. 54, 165-187 (1998).
20. Jackson AC. Pathogenesis In: Rabies. Jackson AC, Wunner AH (Eds). Elsevier Science, Academic Press, CA, USA, 245-282 (2002).
21. Centers for Disease Control. Recovery of a patient from clinical rabies - Wisconsin, USA. Morb. Mortal. Wkly. Rep. 53(50), 1171-1173 (2004).
22. Kuzmin IV, Orciari LA, Arai YT et al. Bat lyssaviruses (Aravan and Khujand) from Central Asia: phylogenetic relationships according to N, P and G gene sequences. Virus Res. 97, 65-79 (2003).
23. Arai YY, Kuzmin IV, Kameoka Y, Botvinkin AI. New lyssavirus genotype from lesser mouse-eared bats (Myotis blythi), Kyrghyzstan. Emerg. Infect. Dis. 9(3), 333-337 (2003). Proposes a new lyssavirus genotype for the Aravan virus, discovered and isolated in 1991 in central Asia.
24. Botvinkin AD, Poleschuk EM, Kuzmin IV et al. Novel lyssaviruses isolated from bats in Russia. Emerg. Infect. Dis. 9(12), 1623-1625 (2003). Reports the recent discovery and isolation of new lyssaviruses from Russia, Irkut and west Caucasian bat viruses.
25. Badrane H, Bahloul C, Perrin P, Tordo N. Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity. J. Virol. 75, 3268-3276 (2001). Definitive paper that describes the partitioning of the lyssavirus genus into two distinct phylogroups and discusses the implications thereof.
26. Von Teichman B, de Koker WC, Bosch SJE, Meredith CD, Bingham J. Mokola virus infection: description of recent South African cases and a review of virus epidemiology. J SA Vet. Assoc. 69(4), 169-171 (1998). Describes the re-emergence of Mokola virus in South Africa.
27. Nel L, Jacobs J, Jaftha J, von Teichman B, Bingham J. New cases of Mokola virus infection in South Africa: A genotypic comparison of southern african virus isolates. Virus Genes 20(2), 103-106 (2000). Describes the re-emergence of Mokola virus in South Africa.
28. Tuffereau C, LeBlois H, Bnjean J, Coulon P, Lafay F, Flamand A. Arginine or lysine in position 333 of ERA and CVS glycoprotein is necessary for rabies virulence in adult mice. Virology 172, 206-212 (1989).
29. Desmezieres E, Maillard AP, Gaudin Y, Tordo N, Perrin P. Differential stability and fusion activity of Lyssavirus glycoprotein trimers. Virus Res. 91, 181-187 (2003).
30. Rupprecht CE, Hanlon CA, Hemachudha T. Rabies re-examined. Lancet Infect. Dis. 2(6), 327-343 (2002).
31. Smith JS. Rabies virus. In: Manual of Clinical Microbiology. Murray PR (Ed.). American Society for Microbiology, Washington DC, USA, 1099-1106 (1999).
32. Dreesen DW. A global review of rabies vaccines for human use. Vaccine 15(Suppl.), S2-S6 (1997).
33. World Health Organization. Field application of oral rabies vaccines for dogs: report of a WHO consultation organized in collaboration with the Office International des Epizootics (OIE). WHO/EMC/ZDI/98.15 (1998).
34. Schumacher CL, Coulon P, Lafay F et al. SAG-2 oral rabies vaccine. Ondentepoort J. Vet. Res. 60, 459-462 (1993).
35. Fekadu M, Nesby SL, Shaddock JH, Schumacher CL, Linhart SB, Sanderlin DW. Immunogenicity, efficacy and safety of an oral rabies vaccine (SAG-2) in dogs. Vaccine 14(6), 465-468 (1996).
36. Wandeler AI. Oral immunization against rabies: afterthoughts and foresight. Schweiz Arch. Tierheilkd. 142, 455-462 (2000).
37. Hammami S, Schumacher C, Cliquet F, Tladi A, Aubert A, Aubert M. Vaccination of Tunisian dogs with the lyophilised SAG2 oral rabies vaccine incorporated into die DBL2 dog bait. Vet. Res. 30, 607-613 (1999).
38. Palanisamy R, Ramanna BC, Ananda Rao K, Srinivasan VA. Combined vaccination of cattle against FMD and rabies. Microbiologica 15(1), 45-49 (1992).
39. Aspden K, van Dijk A, Bingham J, Cox D, Passmore J-A, Williamson A-L. Immunogenicity of a recombinant lumpy skin disease virus (needing vaccine strain) expressing the rabies virus glycoprotein in cattle. Vaccine 20, 2693-2701 (2002).
40. Benmansour A, Leblois H, Coulon P et al. Antigenicity of rabies virus glycoprotein. J. Virol. 65, 4198-4203 (1991).
41. Schneider LG. Antigenic variants of rabies virus. Comp. Immunol. Microbiol. Infect. Dis. 5(1-3), 101-107 (1982).
42. Dietzschold B, Rupprecht CE, Tollis M et al. Antigenic diversity of the glycoprotein and nucleocapsid proteins of rabies and rabies-related viruses: implication for epidemiology and control of rabies. Rev. Infect. Dis. 10, S785-S798 (1988).
43. Fekadu M, Shaddock JH, Sanderlin DW, Smith JS. Efficacy of rabies vaccines against Duvenhage virus isolated from European house bats (Eptesicus serotinus), classic rabies and rabies-related viruses, Vaccine 6, 533-539 (1988). One of the first papers to describe, and then evaluate, the crossprotective potential of rabies vaccines within the lyssavirus genus.
44. Bourhy H, Kissi B, Lafon M, Sacramento D, Tordo N. Antigenic and molecular characterization of bat rabies virus in Europe. J. Clin. Microbiol. 30(9), 2419-2426 (1992).
45. Lafon M, Herzog M, Sureau P. Human rabies vaccines induce neutralising antibodies against the European bat rabies virus (Duvenhage). Lancet 2, 515 (1986).
46. Lafon M, Bourhy H, Sureau P. Immunity against the European bat rabies (Duvenhage) virus induced by rabies vaccines: an experimental study in mice. Vaccine 6, 362-368 (1988). One of the first papers to describe and then evaluate the crossprotective potential of rabies vaccines within the lyssavirus genus.
47. Herzog M, Fritzell C, Lafage M, Montano Hirose JA, Scott-Algara D, Lafon M. T and B cell human responses to European bat lyssavirus after post-exposure rabies vaccination. Clin. Exp. Immunol. 85, 224-230 (1991).
48. Fraser GC, Hooper PT, Lunt RA et al. Encephalitis caused by a Lyssavirus in fruit bats in Australia. Emerg. Infect. Dis. 2(4), 327-331 (1996). Describes the recent discovery and then isolation [49] of the Australian bat lyssavirus, now a new lyssavirus genotype and the first and only lyssavirus genotype encountered in Australia.
49. Hooper PT, Lunt RA, Gould AR et al. A new lyssavirus - the first endemic rabies-related virus recognized in Australia. Bulletin of the Institute Pasteur 95, 209-218 (1997).
50. Bahloul C, Jacob Y, Tordo N, Perrin P. DNA-based immunization for exploring the enlargement of immunological cross-reactivity against the lyssaviruses. Vaccine 16(4), 417-425 (1998).
51. Hanlon CA, Kuzmin I, Blanton JD, Weldon WC, Manangan JS, Rupprecht CE. Efficacy of rabies biologics against new lyssaviruses from Eurasia. Virus Res. 111(1), 44-54 (2005). Important paper examining the efficacy of rabies vaccines and immunoglobulins within the broader lyssavirus genus, not only for vaccination, but for postexposure treatment.
52. Familusi JB, Moore DL. Isolation of a rabies related virus from the CSF of a child with 'aseptic meningitis'. Afr. J. Med. Sci. 3, 93-96 (1972).
53. Familusi JB, Osunkoya BO, Moore DL, Kemp GE, Fabiyi A. A fatal human infection with Mokola virus. Am. J. Trop. Med. Hyg. 21, 959-963 (1972).
54. Tordo N, Bourhy H, Sather S, Ollo R. Structure and expression in baculovirus of the Mokola virus glycoprotein: an efficient recombinant vaccine. Virology 194, 59-69 (1993).
55. Anilionis A, Wunner WH, Curtis PJ. Structure of the glycoprotein gene in rabies virus. Nature 294, 275-278 (1981).
56. Jallet C, Jacob Y, Bahloul C et al. Chimeric lyssavirus glycoproteins with increased immunological potential. J. Virol. 73(1), 225-233 (1999). Describes the potential of chimeric lyssavirus glycoproteins in developing innovative crossprotective lyssavirus vaccines.
57. Aspden K, Passmore J, Tiedt F, Williamson A-L. Evaluation of lumpy skin disease virus, a capripoxvirus, as a replication-deficient vaccine vector. J. Gen. Virol. 84, 1985-1996 (2003).
58. Rupprecht CE, Blass L, Smith K et al. Human infection due to recombinant vaccinia-rabies glycoprotein virus. N. Engl. J. Med. 345, 582-586 (2001).
59. Koprowski K, Yusibov V. The green revolution: plants as heterologous expression vectors. Vaccine 19, 2735-2741 (2001).
60. Hanlon CA, DeMattos CA, DeMattos CC et al. Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis. Vaccine 19, 3834-3842 (2001). Describes the potential of monoclonal antibodies to replace rabies immunoglobulin in the postexposure treatment of rabies infection.
61. Badrane H, Tordo N. Host switching in Lyssavirus history from the Chiroptera to the Carnivora orders. J. Virol. 75, 8096-8104 (2001).
62. Foley HD, McGettigan JP, Siler CA, Dietzschold B, Schnell MJ. A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection. Proc. Natl Acad. Sci. USA 97(26), 14680-14685 (2000).
63. Yarosh OK, Wandeler AI, Graham FL, Campbell JB, Prevec L. Human adenovirus type 5 vectors expressing rabies glycoprotein. Vaccine 14(13), 1257-1264 (1996).
64. WHO position paper. Rabies vaccines. Wkly Epidemiol. Rec. 77, 109-120 (2002).
65. Hughes GJ, Smith JS, Hanlon CA, Rupprecht CE. Evaluation of a TaqMan PCR assay to detect rabies virus RNA: influence of sequence variation and application to quantification of viral loads. J. Clin. Microbiol. 42(1), 299-306 (2004).
66. Pastoret P-P, Kappeler A, Aubert M. European rabies control and its history. In: Historical Perspectives of Rabies in Europe and the Mediterranean Basin. King AA, Fooks AR, Aubert M, Wandeler AI (Eds). World Organisation for Animal Health, Paris, France, 337-359 (2004).
67. King A, Crick J. Rabies-related viruses. In: Rabies. Campbell JB, Charlton KM (Eds), Kluwer academic publishers, BA, USA 177-200 (1988).
68. Schnell MJ, Tan GS, Dietzschold B. The application of reverse genetics technology in the study of rabies virus (RV) pathogenesis and for the development of novel RV vaccines. J. NeuroVirology 11(1), 76-81 (2005). Describes the application of reverse genetics to the virus genome and discusses the importance of the technology in the development of new and better lyssavirus vaccines.
69. Fooks AR. The challenge of new and emerging lyssaviruses. Exp. Rev. Vaccines 3(4), 89-92 (2004). Presents a concise and updated review of new and emerging lyssaviruses and the challenges they hold in developing future strategies of control and treatment.
70. Mebatsion T, Cox JH, Frost JW. Isolation and characterization of 115 street rabies virus isolates from Ethiopia by using monoclonal antibodies: identification of 2 isolates as Mokola and Lagos Bat viruses. JIV 166, 972-977 (1992).
71. Brookes SM, Parsons G, Johnson N, McElhinney LM, Fooks AR. Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses. Vaccine 23, 4101-4109 (2005). Most recent paper to investigate crossprotecting immune responses elicited by a modern commercial rabies vaccine, specifically as it applies to European bat lyssaviruses 1 and 2 and Australian bat lyssavirus.